336 related articles for article (PubMed ID: 18297518)
1. Iron overload in myelodysplastic syndromes.
Mahesh S; Ginzburg Y; Verma A
Leuk Lymphoma; 2008 Mar; 49(3):427-38. PubMed ID: 18297518
[TBL] [Abstract][Full Text] [Related]
2. Iron overload in myelodysplastic syndromes (MDS).
Gattermann N
Int J Hematol; 2018 Jan; 107(1):55-63. PubMed ID: 29177643
[TBL] [Abstract][Full Text] [Related]
3. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.
Shenoy N; Vallumsetla N; Rachmilewitz E; Verma A; Ginzburg Y
Blood; 2014 Aug; 124(6):873-81. PubMed ID: 24923296
[TBL] [Abstract][Full Text] [Related]
4. Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy.
Shammo JM; Komrokji RS
Expert Rev Hematol; 2018 Jul; 11(7):577-586. PubMed ID: 29902097
[TBL] [Abstract][Full Text] [Related]
5. Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes.
Kattamis A; Aydinok Y; Taher A
Eur J Haematol; 2018 Sep; 101(3):272-282. PubMed ID: 29904950
[TBL] [Abstract][Full Text] [Related]
6. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
[TBL] [Abstract][Full Text] [Related]
7. Pathophysiological and clinical aspects of iron chelation therapy in MDS.
Gattermann N
Curr Pharm Des; 2012; 18(22):3222-34. PubMed ID: 22571702
[TBL] [Abstract][Full Text] [Related]
8. Iron overload in patients with myelodysplastic syndromes.
Jensen PD
Curr Hematol Malig Rep; 2007 Feb; 2(1):13-21. PubMed ID: 20425384
[TBL] [Abstract][Full Text] [Related]
9. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
Leitch HA; Vickars LM
Hematology Am Soc Hematol Educ Program; 2009; ():664-72. PubMed ID: 20008252
[TBL] [Abstract][Full Text] [Related]
10. Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.
Imran F; Phatak P
Expert Rev Hematol; 2017 Jan; 10(1):53-64. PubMed ID: 27923273
[TBL] [Abstract][Full Text] [Related]
11. Iron chelation therapy for a case of transfusion-independent MDS-RARS with significant iron overload.
Ohashi H; Arita K; Suzuki Y; Tomita A; Naoe T; Hattori A; Tatsumi Y; Kato K; Nagai H
Int J Hematol; 2013 Jan; 97(1):151-3. PubMed ID: 23208667
[No Abstract] [Full Text] [Related]
12. Management of transfusion-related iron overload in patients with myelodysplastic syndromes.
Shah J; Kurtin SE; Arnold L; Lindroos-Kolqvist P; Tinsley S
Clin J Oncol Nurs; 2012 Jun; 16 Suppl():37-46. PubMed ID: 22641283
[TBL] [Abstract][Full Text] [Related]
13. Iron overload in myelodysplastic syndromes: diagnosis and management.
List AF
Cancer Control; 2010 Jan; 17 Suppl():2-8. PubMed ID: 20125080
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes.
Cazzola M; Della Porta MG; Malcovati L
Hematology Am Soc Hematol Educ Program; 2008; ():166-75. PubMed ID: 19074076
[TBL] [Abstract][Full Text] [Related]
15. Iron overload and chelation therapy in myelodysplastic syndromes.
Temraz S; Santini V; Musallam K; Taher A
Crit Rev Oncol Hematol; 2014 Jul; 91(1):64-73. PubMed ID: 24529413
[TBL] [Abstract][Full Text] [Related]
16. [Myelodysplastic syndromes and iron metabolism].
Kawabata H
Rinsho Ketsueki; 2018; 59(10):2042-2049. PubMed ID: 30305507
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of deferasirox in myelodysplastic syndromes.
Breccia M; Alimena G
Ann Hematol; 2013 Jul; 92(7):863-70. PubMed ID: 23417759
[TBL] [Abstract][Full Text] [Related]
18. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
19. Do Recent Randomized Trial Results Influence which Patients with Myelodysplastic Syndromes Receive Iron Chelation?
Gattermann N
Hematol Oncol Clin North Am; 2020 Apr; 34(2):465-473. PubMed ID: 32089223
[TBL] [Abstract][Full Text] [Related]
20. When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?
Steensma DP; Gattermann N
Best Pract Res Clin Haematol; 2013 Dec; 26(4):431-44. PubMed ID: 24507819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
